DigitalDx Ventures

Oxford Cancer Analytics develops an AI-based platform for early cancer detection via blood testing. It analyzes liquid biopsy results from DNA, proteins, epigenetics, epidemiology, and medical history, enabling healthcare providers to identify cancers early and initiate curative treatment.

NOWDiagnostics develops and manufactures rapid diagnostic tests that use a single drop of blood, providing results within minutes. Its ADEXUSDx product line offers tests for common conditions like pregnancy, heart attack, and toxicology, empowering patients and caregivers with immediate healthcare insights.

Biotia, Inc. is a health technology company based in New York, founded in 2016. It specializes in developing software and laboratory technologies that leverage next-generation DNA sequencing and artificial intelligence to enhance infectious disease discovery and management. By providing tailored microbial surveillance, Biotia's innovative solutions enable clinicians and researchers to identify and mitigate pathogens effectively, thereby reducing hospital-acquired infections and improving patient outcomes. The company's technology empowers healthcare professionals to guide treatment decisions proactively, ultimately aiming to prevent illnesses before they occur.

GLX Analytix combines proprietary blood biomarkers with AI to pioneer personalized medicine. Its platform enables earlier diagnosis and optimized treatment plans for various diseases such as neurodegeneration, autoimmunity, cardiovascular disorders, and neuropsychiatric conditions.

Founded in 2013, Trayt is a healthcare technology company based in Redwood City, California. It specializes in developing data analytics tools designed to enhance the diagnosis and treatment of patients with brain-based disorders. The company's platform enables clinicians to track, measure, and share behavioral and medical outcomes, improving care coordination.

Optina Diagnostics is a diagnostics company focusing on retinal imaging and artificial intelligence to provide non-invasive tests that detect signs of neurodegenerative and ocular diseases. By analyzing retinal images, it identifies biomarkers associated with Alzheimer's disease, as well as eye conditions like age-related macular degeneration and diabetic retinopathy, enabling clinicians to assess brain health and disease risk early. The platform aims to support timely diagnosis and treatment decisions with a simple eye exam.

NephroSant is an innovative diagnostic startup established by a team of physicians and experts in science, engineering, and clinical research, dedicated to enhancing global kidney health. The company has developed a urine-based diagnostic tool that enables the quantitative measurement of biomarkers crucial for the early detection and ongoing monitoring of kidney disease. This noninvasive tool is particularly valuable for physicians, as it aids in predicting and preventing the progression of kidney disease and facilitates the early detection of acute rejection in kidney transplant patients. Through their research-driven approach, NephroSant aims to significantly improve patient outcomes in kidney health.

Founded in 2013, Trayt is a healthcare technology company based in Redwood City, California. It specializes in developing data analytics tools designed to enhance the diagnosis and treatment of patients with brain-based disorders. The company's platform enables clinicians to track, measure, and share behavioral and medical outcomes, improving care coordination.

Delphi Diagnostics specializes in developing innovative diagnostic tools for breast cancer. Its flagship product is the Endocrine Activity Index (EAI) test, which measures endocrine activity in hormone receptor positive, HER2 negative breast cancer patients. This test aims to improve prognosis and treatment prediction, enabling personalized care.

AEENA Dx is a biotechnology company focused on developing a saliva-based platform for the detection of cancer and other diseases. The company specializes in biofluid-based molecular diagnostic tests that aim to enhance breast cancer screening and diagnosis. By improving the sensitivity and specificity of existing mammography programs, AEENA Dx seeks to make breast cancer detection more accurate, accessible, and affordable for women. This innovative approach allows patients to easily identify potential health issues related to breast cancer, enabling them to take timely measures for prevention and treatment.

Optina Diagnostics is a diagnostics company focusing on retinal imaging and artificial intelligence to provide non-invasive tests that detect signs of neurodegenerative and ocular diseases. By analyzing retinal images, it identifies biomarkers associated with Alzheimer's disease, as well as eye conditions like age-related macular degeneration and diabetic retinopathy, enabling clinicians to assess brain health and disease risk early. The platform aims to support timely diagnosis and treatment decisions with a simple eye exam.